Analysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Price Target at $68.29

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have earned an average recommendation of “Moderate Buy” from the seventeen research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and fifteen have issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $62.6875.

Several research analysts recently commented on RARE shares. Wedbush reiterated a “neutral” rating and issued a $25.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, February 17th. JPMorgan Chase & Co. decreased their price objective on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a research report on Thursday, March 12th. Guggenheim lowered their price objective on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research note on Monday, January 5th. Canaccord Genuity Group dropped their target price on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a report on Wednesday, February 18th. Finally, Wells Fargo & Company cut their target price on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 30th.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE opened at $21.82 on Tuesday. The stock has a market capitalization of $2.11 billion, a PE ratio of -3.74 and a beta of 0.16. The company’s fifty day moving average is $22.99 and its 200 day moving average is $28.75. Ultragenyx Pharmaceutical has a fifty-two week low of $18.41 and a fifty-two week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The business had revenue of $207.28 million during the quarter, compared to analysts’ expectations of $199.60 million. During the same period in the previous year, the business earned ($1.39) earnings per share. The business’s quarterly revenue was up 25.5% on a year-over-year basis. As a group, research analysts forecast that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 54,404 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $1,240,411.20. Following the completion of the transaction, the chief executive officer directly owned 658,994 shares of the company’s stock, valued at approximately $15,025,063.20. The trade was a 7.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Erik Harris sold 10,539 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $240,289.20. Following the transaction, the executive vice president owned 89,515 shares in the company, valued at $2,040,942. The trade was a 10.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 104,958 shares of company stock valued at $2,394,858. Insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Assetmark Inc. lifted its stake in shares of Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares during the last quarter. Huntington National Bank boosted its holdings in Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 393 shares during the period. Danske Bank A S bought a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at $39,000. Smartleaf Asset Management LLC grew its position in Ultragenyx Pharmaceutical by 205.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 1,169 shares during the last quarter. Finally, Covestor Ltd increased its stake in Ultragenyx Pharmaceutical by 26.0% in the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 369 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: One press release in the batch concerns a different “RARE” ticker (Tactical Resources Corp.) and is unrelated to Ultragenyx; it should be ignored for Ultragenyx-specific analysis. Tactical Resources Signs Agreement to Acquire the Sierra Blanca Quarry and Tailings Access for the Peak Rare Earth Project
• Negative Sentiment: Multiple national plaintiff firms (Rosen, Faruqi & Faruqi, Portnoy, Schall, Berger Montague, Bronstein Gewirtz & Grossman) have announced a class action or are soliciting lead‑plaintiff applicants for the same alleged class period (Aug 3, 2023–Dec 26, 2025), urging investors to act before the April 6, 2026 deadline — increasing the chance of coordinated litigation and potential settlement exposure. ROSEN, A TOP RANKED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RARE
• Negative Sentiment: Faruqi & Faruqi issued a reminder about the April 6 lead‑plaintiff deadline and is investigating potential claims against Ultragenyx — another prominent firm publicizing the suit, which can increase publicity and plaintiff coordination. RARE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
• Negative Sentiment: Portnoy Law Firm announced a class action on behalf of Ultragenyx investors covering the same class period and deadline, adding to the number of active plaintiffs’ firms. Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors
• Negative Sentiment: Schall Law Firm is soliciting lead‑plaintiff applicants for a securities fraud suit alleging violations of Sections 10(b) and 20(a); the legal claims are being actively marketed to investors which can amplify headline risk. RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
• Negative Sentiment: Berger Montague published a securities-fraud notice about a filed class action covering the same dates and the April 6 deadline, increasing the number of firms involved. ULTRAGENYX PHARMACEUTICAL INC. SECURITIES FRAUD NOTICE: Berger Montague Informs Ultragenyx Pharmaceutical Inc. (RARE) Investors of a Securities Fraud Lawsuit
• Negative Sentiment: Bronstein, Gewirtz & Grossman also alerted investors to a class action alleging investor harm and the same April 6 deadline — another sign of broad plaintiff interest. Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.